Online citations, reference lists, and bibliographies.

Effect Of Increasing Experience On Dosimetric And Clinical Outcomes In The Management Of Malignant Pleural Mesothelioma With Intensity-modulated Radiation Therapy.

P. Patel, S. Yoo, G. Broadwater, L. Marks, E. Miles, T. D’amico, D. Harpole, C. Kelsey
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To assess the impact of increasing experience with intensity-modulated radiation therapy (IMRT) after extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM). METHODS AND MATERIALS The records of all patients who received IMRT following EPP at Duke University Medical Center between 2005 and 2010 were reviewed. Target volumes included the preoperative extent of the pleural space, chest wall incisions, involved nodal stations, and a boost to close/positive surgical margins if applicable. Patients were typically treated with 9-11 beams with gantry angles, collimator rotations, and beam apertures manually fixed to avoid the contalateral lung and to optimize target coverage. Toxicity was graded retrospectively using National Cancer Institute common toxicity criteria version 4.0. Target coverage and contralateral lung irradiation were evaluated over time by using linear regression. Local control, disease-free survival, and overall survival rates were estimated using the Kaplan-Meier method. RESULTS Thirty patients received IMRT following EPP; 21 patients also received systemic chemotherapy. Median follow-up was 15 months. The median dose prescribed to the entire ipsilateral hemithorax was 45 Gy (range, 40-50.4 Gy) with a boost of 8-25 Gy in 9 patients. Median survival was 23.2 months. Two-year local control, disease-free survival, and overall survival rates were 47%, 34%, and 50%, respectively. Increasing experience planning MPM cases was associated with improved coverage of planning target volumes (P=.04). Similarly, mean lung dose (P<.01) and lung V5 (volume receiving 5 Gy or more; P<.01) values decreased with increasing experience. Lung toxicity developed after IMRT in 4 (13%) patients at a median of 2.2 months after RT (three grade 3-4 and one grade 5). Lung toxicity developed in 4 of the initial 15 patients vs none of the last 15 patients treated. CONCLUSIONS With increasing experience, target volume coverage improved and dose to the contralateral lung decreased. Rates of pulmonary toxicity were relatively low. However, both local and distant control rates remained suboptimal.
This paper references
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
Aphase II trial of surgical resection and adjuvant high - dose hemithoracic radiation for malignant pleural mesothelioma
CA Kristensen (2001)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.IJROBP.2005.06.006
Effectiveness of noncoplanar IMRT planning using a parallelized multiresolution beam angle optimization method for paranasal sinus carcinoma.
X. Wang (2005)
10.1016/0003-4975(94)91066-9
Aggressive multimodality therapy for malignant pleural mesothelioma.
T. Rice (1994)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/j.ijrobp.2007.11.011
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
E. Miles (2008)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
10.1016/j.radonc.2009.03.011
Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.
C. Kristensen (2009)
10.1016/J.IJROBP.2007.03.011
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
D. Rice (2007)



This paper is referenced by
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.3978/j.issn.2072-1439.2013.08.46
Recent advances in radiotherapy for thoracic tumours.
M. Fay (2013)
10.21037/atm.2017.06.25
Malignant pleural mesothelioma: adjuvant therapy with radiation therapy.
K. Rosenzweig (2017)
10.1016/j.cllc.2018.04.019
Utilization of Intensity‐Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States
Sherif G Shaaban (2018)
10.1080/0284186X.2017.1279749
Long-term outcomes of intensity-modulated radiotherapy following extra-pleural pneumonectomy for malignant pleural mesothelioma
Yukinori Matsuo (2017)
10.1007/978-3-319-52619-5_36-1
Radiation Therapy in Mesothelioma
Jonas Willmann (2019)
10.1007/s11547-019-01030-y
Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy
Marco Trovò (2019)
10.1586/17476348.2013.838016
Advances in the management of pleural disease
John P Corcoran (2013)
10.1245/s10434-019-07235-9
The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma
Gary D Lewis (2019)
10.1016/J.CANRAD.2018.05.003
Chimioradiothérapie des cancers de l’œsophage : revue critique de la littérature
Eivind Blais (2019)
10.1080/0284186X.2019.1691257
Knowledge-based planning for oesophageal cancers using a model trained with plans from a different treatment planning system
Y. Ueda (2019)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
Marc de Perrot (2017)
10.1007/s13566-017-0299-2
Radiation therapy for localized malignant pleural mesothelioma: a propensity score-matched analysis of the National Cancer Data Base
Nisha Ohri (2017)
10.1016/j.rpor.2019.09.002
Cardiotoxicity of mediastinal radiotherapy.
Ivica Ratosa (2019)
10.1093/jrr/rru102
Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy
Tomoki Kimura (2015)
10.21037/tlcr.2017.06.03
Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.
Licun Wu (2017)
10.1007/174_2017_27
Lung Cancer and Other Thoracic Malignancies
Matthew M. Harkenrider (2017)
10.1155/2019/4568958
Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma
Berrin Pehlivan (2019)
10.3978/j.issn.2225-319X.2012.11.07
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
C. Cao (2012)
10.1016/j.canrad.2016.09.009
Radiation therapy for malignant pleural mesothelioma.
Kenneth E. Rosenzweig (2017)
10.1111/1759-7714.12860
Intensity‐modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma
M. Simon (2018)
10.1186/s13014-015-0575-5
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy
C. Thieke (2015)
10.7759/cureus.1705
Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy
Howard D. Lee (2017)
10.1016/J.CANRAD.2017.07.046
Doses aux organes à risque en radiothérapie conformationnelle et en radiothérapie stéréotaxique : les poumons
Eivind Blais (2017)
10.1016/j.jtho.2017.02.026
Improved Outcomes with Modern Lung‐Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma
F. Shaikh (2017)
10.1016/j.adro.2017.01.011
Functional image guided radiation therapy planning in volumetric modulated arc therapy for patients with malignant pleural mesothelioma
Y. Doi (2017)
10.1111/ajco.12680
Intensity modulated radiation therapy after extra‐pleural pneumonectomy for malignant pleural mesothelioma is feasible without fatal pulmonary toxicity and provides good survival
Sameer Jhavar (2018)
10.2217/LMT.15.16
Multimodality therapy for malignant pleural mesothelioma: surgery plus chemoradiotherapy?
Andrea S. Wolf (2015)
10.3978/j.issn.2225-319X.2012.10.07
Novel radiation therapy approaches in malignant pleural mesothelioma.
A. Rimner (2012)
10.1007/s00066-015-0901-8
Tomotherapy PET-guided dose escalation
Angelo Maggio (2015)
10.1111/1759-7714.12008
Role of new radiation techniques in the treatment of pleural mesothelioma.
Maurizio Amichetti (2013)
10.1007/978-3-319-28761-4_20
Modern Radiotherapy Techniques in Malignant Pleural Mesothelioma
Gokhan Ozyigit (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar